What is Nabla Bio?
Headquartered in Cambridge, Massachusetts, Nabla Bio operates at the vanguard of the biotechnology sector. The company specializes in the development of an AI-driven platform designed to accelerate the discovery and optimization of complex protein therapeutics. By integrating machine learning with high-throughput experimental validation, Nabla Bio addresses critical bottlenecks in drug development, specifically targeting the design of antibodies and other biologics with high specificity and efficacy. This technological approach allows the company to navigate complex biological landscapes that have historically challenged traditional drug discovery methods, effectively positioning it as a high-growth entity within the precision medicine ecosystem.
How much funding has Nabla Bio raised?
Nabla Bio has raised a total of $37M across 2 funding rounds:
Angel/Seed
$11M
Series A
$26M
Angel/Seed (2021): $11M with participation from Cantos Ventures, Zetta Venture Partners, Fifty Years, and Khosla Ventures
Series A (2024): $26M led by Bristol-Myers Squibb, Takeda, AstraZeneca, and Radical Ventures
Key Investors in Nabla Bio
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, focusing on breakthrough technologies across sectors including health, AI, and sustainable energy.
Bristol-Myers Squibb
A global biopharmaceutical leader dedicated to discovering and developing innovative medicines for oncology, cardiovascular, and immunoscience therapeutic domains.
Takeda
A research-driven global pharmaceutical company with a long history of innovation in gastroenterology, oncology, neuroscience, and rare disease therapies.
What's next for Nabla Bio?
With the recent infusion of capital, Nabla Bio is well-positioned to scale its proprietary platform and advance its internal pipeline of therapeutic candidates. The strategic involvement of major biopharmaceutical partners suggests a clear trajectory toward clinical validation and potential co-development agreements. As the company matures, the focus will likely shift toward expanding its computational infrastructure and deepening its research capabilities to tackle increasingly complex disease targets. This phase of growth is critical for transitioning from a technology-focused startup to a clinical-stage biopharmaceutical innovator, with the backing of both deep-tech venture firms and industry incumbents providing the necessary resources to sustain long-term R&D cycles.
See full Nabla Bio company page
